Document:

Unassociated Document

    Exhibit 10.28

     

    PRODUCTION
AGREEMENT

     

    This
Production Agreement (“Agreement”) is made and entered into as of this 26th day
of January, 2007 by and between AVAX Technologies, Inc., a New York corporation
with headquarters located at 2000 Hamilton Street Suite 204, Philadelphia,
Pennsylvania 19130 (“AVAX”), and Cancer Treatment Centers of America, Inc., an
Illinois corporation with headquarters located at 1336 Basswood Road,
Schaumburg, Illinois 60173 (“CTCA”).

     

    RECITALS

     

    
      	  	
              A.

            	
              CTCA
      manages certain oncology specialty hospitals and physician practices in
      Zion, Illinois (“MRMC”); Tulsa, Oklahoma (“SRMC”); and Philadelphia,
      Pennsylvania (“ERMC”, and together with MRMC and SRMC and others that CTCA
      may develop in the future, collectively referred to as “CTCA
      Facilities”).

            

    

     

    
      	  	
              B.

            	
              AVAX
      is in the business of the development and commercialization of
      individualized vaccine therapies and small molecules for the treatment of
      cancer and other life-threatening diseases. AVAX has represented to CTCA
      that AVAX owns a dormant GMP laboratory in Philadelphia, Pennsylvania (the
      “Philadelphia Laboratory” or “Philadelphia Lab”), which AVAX is capable of
      reactivating and obtaining FDA permission to use to manufacture
      products.

            

    

     

    
      	  	
              C.

            	
              AVAX
      has further represented that AVAX is capable of producing autologous
      haptenized cancer vaccines (“Vaccines”) and heterologous haploidentical,
      IL2-activated NK cells (“IL2NK
Cells”).

            

    

     

    
      	  	
              D.

            	
              CTCA
      desires to retain AVAX to produce Vaccines and IL2NK Cells, and AVAX is
      willing to produce them on the terms and conditions contained in this
      Agreement.

            

    

     

    AGREEMENTS

     

    For and
in consideration of the mutual covenants contained herein, and other valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto agree as follows:

     

    1.    
Retention of
AVAX. CTCA hereby agrees to retain
AVAX to produce CTCA’S requirements of Vaccines and IL2NK Cells for a period of
three (3) years from the date of this Agreement.

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    2.    
Obligations of AVAX
with Regard to GMP Lab. AVAX will
secure FDA agreement to manufacture clinical materials, and maintain and operate
the Philadelphia Laboratory in compliance with all FDA and other federal
regulations that govern the licensing of GMP laboratories that produce products
for use in humans, as well as in compliance with all state and local regulations
and laws, including laws relating to the handling and disposal of biological and
hazardous waste materials. It is understood and agreed that the FDA does not
provide a formal license for the authorization of the production of products
used in clinical studies that are the subject of an Investigational New Drug
Application (IND).

     

    3.    
Obligations of CTCA
with Regard to GMP Lab. Once AVAX
has performed its obligations set forth in paragraph 2 above, CTCA will
purchase, install and maintain service contract coverage for: one (1) cell
separator/concentrator device from the Miltenyi Biotec Corporation (or such
other provider acceptable to CTCA in its reasonable discretion); and, one (1)
FC500 Coulter Flow Cytometer for use by AVAX in its GMP laboratory for the
preparation and characterization of IL2NK cell preparations. These devices will
be owned by CTCA but maintained and operated by AVAX for the exclusive use of
CTCA. In the event that CTCA purchases any other capital equipment for use in
AVAX’s GMP lab, such equipment shall remain the property of CTCA. CTCA will bear
the cost for removing any CTCA equipment to ensure non-interruption of the GMP
Facility. Notwithstanding the foregoing, in no event shall CTCA’s financial
obligations for the purchase of equipment under this Section 3 exceed Two
Hundred Fifty Thousand Dollars ($250,000).

     

    4.    
AVAX’s Production
Requirements. AVAX will produce a
combined total of up to 40 usable preparations consisting of autologous Vaccines
and/or IL2NK cell therapy products annually. CTCA will handle all tumor samples
in an aseptic fashion and will place them into the agreed upon shipping box to
avoid sample contamination. In the event there is excessive contamination of
samples as, reasonably determined by AVAX, upon notice to CTCA, corrective
actions will be implemented at CTCA Facilities.

     

    (a)  
Vaccines. The number of each product will depend on
patient accrual by CTCA. Source material for autologous cancer vaccines will
consist of patient tumor tissues collected at CTCA hospitals, and shipped to
AVAX. Usable Vaccines shall be defined according to the definition developed by
AVAX for its clinical trials. All vaccines released by AVAX in accordance with
its manufacturing protocol in compliance with FDA approved release criteria will
be counted in the total number of preparations/year.

     

    (b) IL2NK Cells. Source material for IL2NK
Cells shall consist of leukapheresis preparations collected from donors at the
MRMC and shipped to AVAX. All IL2NK cell preparations released by AVAX in
accordance with its manufacturing protocol in compliance with FDA approved
release criteria will be counted in the total number of
preparations/year.

     

    (c) Quality assurance, quality
control of production.
AVAX will be responsible for all performance quality control aspects of
manufacturing, and characterization and quality assurance of all manufactured
products.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    (d) Tissue Handling and
Shipping. AVAX will handle and
process all tissues received from CTCA facilities, and ship to CTCA facilities
all products produced by AVAX in its GMP facility, in compliance with all FDA
and other federal regulations that govern the handling, processing and shipping
of products for use in humans.

     

    5.    
AVAX’s Obligations
Prior to Opening GMP Lab. Prior to the opening of the
Philadelphia GMP laboratory, AVAX will manufacture for CTCA up to the 40
vaccines/year in support of CTCA’s protocol for advanced, recurrent ovarian
cancer that will be conducted under the IND held by AVAX for this indication.
CTCA and AVAX will collaborate in the registration and activation of this trial,
which will go to the MRMC Institutional Review Board of CTCA no later than 3
months following execution of this Agreement.

     

    6.    
Compensation, Payments
and Repayments. In consideration of
AVAX’s production and delivery of the Vaccines and the IL2NK Cells, CTCA will
make the following payments to AVAX:

     

    (a) Initial Payment and
Repayment Obligations. CTCA will
make a conditional payment to AVAX in the amount of $250,000 upon execution of
this Agreement, which funds will be used by AVAX solely to initiate actions
needed to manufacture clinically acceptable products in the Philadelphia GMP
Laboratory and generate documents and process development efforts that will lead
to the manufacture of Vaccines and/or the IL2NK Cells.

     

    (i) In
the event that AVAX fails to be ready to deliver to CTCA Vaccine or IL2NK Cells
produced in Philadelphia within 15 months following execution of this Agreement,
AVAX will refund to CTCA $125,000 of such payment.

     

    (ii) If
AVAX fails to be ready to deliver vaccines or cell therapy products manufactured
in the Philadelphia facility within 18 months following inception of this
agreement, AVAX agrees to refund to CTCA an additional $125,000.

     

    (iii) To
secure repayment by AVAX of the amounts set forth in subparagraphs (i) and (ii)
above, AVAX will grant to CTCA a first priority security interest in all of the
personal property comprising the Philadelphia GMP laboratory at the time that
CTCA advances the $250,000

     

    (b) Monthly Payments and
Abatement. CTCA will pay AVAX
$25,000 monthly for activities including facility validation and maintenance and
production of vaccines and/or cell therapy products produced in AVAX’s
Philadelphia GMP laboratory beginning the day the FDA allows AVAX to produce product for human use in that
facility (which is noted above in Section 2 of this
agreement and appended as Exhibit I); provided, however, CTCA will pay AVAX no
monthly fee for the first 90 days following execution of this
Agreement.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    (c) Catch-up Payment. CTCA will pay AVAX, in one
lump sum payment, the accrued monthly fees of $25,000 per month on the day the
FDA allows AVAX to produce product for human use in AVAX’s Philadelphia facility
(which is noted in Section 2 above). The payment will not exceed $150,000. Fee
accrual begins 90 days after execution of this Agreement and ends the day the
FDA allows AVAX to produce product for human use.

     

    (d) Additional
Payments. In consideration of
additional vaccine program(s) in support of other trials activated by CTCA for
other indications, CTCA shall pay AVAX the following amounts:

     

    (i)
$75,000 for development and approval of a supporting IND and associated process
development for vaccines for tumor site other than ovarian cancer; it is
expressly understood and agreed that during the term of this Agreement, CTCA
shall have the right to add new trials involving NK cells at no additional cost
to CTCA so long as the production process does not deviate from the production
process then in place; and

     

    (ii)
$150,000 to initiate non-vaccine products or activated NK cell products that are
consistent with the continued production of vaccines and activated NK cells and
which both parties agree to produce, and will include the development of an
acceptable IND, process development for manufacturing and an acceptable testing
regimen and stability protocol.

     

    (e) Payment for Products in Excess of the
Required 40. In the event that CTCA requires AVAX to produce Vaccines or
IL2NK Cells in excess of forty (40) during any calendar year during the term of
this Agreement, CTCA will pay to AVAX $7,500.00 per additional Vaccine or IL2NK
Cell produced and delivered.

     

    7. Operational Obligations of
CTCA. During the term of this
Agreement, CTCA shall perform the following obligations, it being expressly
agreed that CTCA’s failure to perform any of these obligations will NOT excuse
AVAX’s performance of its production requirements set forth in paragraph 4
above:

     

    (a)  
IND and IRB
Approvals. CTCA will use
commercially reasonable efforts to obtain IND and IRB approval at CTCA-managed
hospital facilities for all treatment protocols that use products produced by
AVAX in its GMP laboratory.

     

    (b)  
Clinical Trial
Conduct. CTCA will conduct all
clinical trials that use products produced by AVAX in its GMP laboratory
according to the IND and IRBapproved protocols in compliance with relevant 21
CFR guidelines, ICH Guidelines for Good Clinical Practice, and applicable
national guidelines and laws.

     

    (c)   Vaccine
Results. CTCA will provide to AVAX for its use,
all clinical results collected on patients treated with the vaccines produced by
AVAX utilizing its proprietary technology on
behalf of CTCA on the Forms provided for the study which have been developed by
AVAX. Such data will be patient de-identified.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    (d)  
Cell Prep
Results. CTCA will share all
clinical results collected on patients treated with the IL2NK cell preparations
produced by AVAX on behalf of CTCA.

     

    
      	
               
      

            	
              8.

            	
              Intellectual Property
      Provisions.

            

    

     

    (a) Vaccines Discovery,
Invention or other Intellectual Property. CTCA agrees that any discovery, invention or
other intellectual property relating to the Vaccines that may be developed by
AVAX during the conduct of this Agreement shall be the sole property of
AVAX.

     

    (b) IL2NK Discovery, Invention
or other Intellectual Property. The parties each agree that any
discovery, invention or other intellectual property that may be developed in the
production and clinical testing of IL2NK Cells as a result of this Agreement
shall be owned jointly and
equally by AVAX and CTCA. AVAX hereby agrees that CTCA shall have the
right to assign ownership of its portion of such discovery, invention or other
intellectual property to International Capital and Management Company, LLLP or
other assignee with common ownership and AVAX hereby consents to any such
assignment. Any further commercial use of such discovery, invention or other
intellectual property shall require mutual approval, and AVAX and CTCA shall
share equally in any royalties accruing from such commercial use. Each party
agrees that any results, discoveries or inventions discovered during the conduct
of this agreement will not be disclosed to outside third parties until both
sides have agreed that the subject matter is not-patentable. In the event a
discovery is patentable CTCA and AVAX will share equally in the patent
costs.

     

    (c)    General Disclosure
Provision. Each party will disclose any and all such discoveries to the other
and will not disclose this information to any third party without the express
written consent of the other party.

     

    
      	
               
      

            	
              9.

            	
              Indemnification and
      Insurance.

            

    

     

    (a)
Indemnification. AVAX hereby agrees to indemnify and defend CTCA, CTCA
Facilities and their respective officers, directors, shareholders, employees,
staff and physicians (collectively, the “Indemnitees”) from and against any
injury (or alleged injury) to patients caused by their use of a Vaccine or IL2NK
Cells product delivered by AVAX which fails to meet protocol specifications. In
connection with such defense obligations, AVAX hereby waives its right to select
counsel for the Indemnitees and shall allow the Indemnitees to utilize defense
counsel of their choice for any claim filed by a patient of an
Indemnitee.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    (b)  
Insurance. AVAX agrees that at all times during the term of this Agreement, AVAX
will purchase and maintain in force property/casualty and liability (including
general liability and products liability) insurance policies covering the
Philadelphia Laboratory, the capital equipment purchased by CTCA under this
Agreement and all products produced by AVAX for CTCA under this Agreement. AVAX
will also purchase and maintain other types of insurance required by law or
typical of similar businesses, covering the Philadelphia Laboratory, its
products and activities. All such insurance policies will be issued by reputable
carriers, acceptable to CTCA in its reasonable discretion, and will contain name
CTCA as an “additional insured”. Policy limits for all liability insurance will
in no event be less than $5,000,000, and for property insurance shall be not
less than the estimated value of the Philadelphia Laboratory plus all capital
equipment purchase by CTCA hereunder. AVAX will provide CTCA with certificates
evidencing such coverage from time to time upon request.

     

    10.  
HIPAA. AVAX
will execute CTCA’s standard “business associate agreement” and will comply with
HIPAA and other federal and state regulations governing the use of personal
health information.

     

    11.  
Option to Operate in
the Event of Change of Ownership or Cessation of Lab Operation. AVAX agrees that any transaction wherein it may
be acquired by another corporation or entity will not recuse AVAX or its
subsequent owner of its obligations to CTCA under this agreement. In the event
that AVAX does not produce the Vaccines and IL2NK Cells as required by this
Agreement or experiences a substantial decline in operational activity at the
Philadelphia Laboratory during the term of this Agreement, CTCA will have the
right, but not the obligation, to take ownership and operational control of the
Philadelphia Lab, including taking an assignment of the real estate lease
covering the Philadelphia Lab and all licensure, contents, equipment and
inventory then located in or associated with the operation of the Philadelphia
Lab. In order to assert such right, CTCA shall provide written notice to AVAX of
CTCA’s intent to exercise its rights set forth in the prior
sentence.

     

    12.  
Early Termination of
Agreement. In the event that either
party desires to terminate this Agreement before the end of the three (3) year
period, that party must provide written notice to the other a minimum of 120
days prior to the early termination date. In the event that CTCA wishes to
terminate this Agreement, it will pay AVAX the sum of $100,000. In the event
that AVAX desires to terminate the Agreement, it will reimburse CTCA an amount
equal to the $250,000 startup cost prorated based on the remaining term of this
Agreement following the 120-day termination period and shall trigger CTCA’s
rights set forth in paragraph 11 above.

     

    13.  
Severability. The provisions of this Agreement shall be
severable, and if any provision of this Agreement shall be held or declared to
be illegal, invalid or unenforceable, such provision shall, if possible, be
limited or construed so as to make it valid and enforceable or, if such
limitation or construction is not possible or would be contrary to the parties’
manifest intentions, such provision shall be stricken from this Agreement. In
any event, the remainder of this Agreement shall continue in full force and
effect.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    14.  
No
Assignment. This Agreement may not
be assigned by either party except that CTCA shall have the right to assign its
rights and obligations hereunder to an affiliate of CTCA so long as such party
assumes the assigned obligations in writing.

     

    15.  
Governing
Law. This Agreement is deemed to be
made and entered into pursuant to the laws of the State of Illinois. In the
event of any dispute hereunder, this Agreement shall be governed by and shall be
construed and interpreted in accordance with the laws of the State of
Illinois.

     

    16.  
Waiver. The terms of this Agreement may be waived, and
this Agreement may be amended, only in writing signed by the party to be bound
thereby. A waiver of one term shall not be construed as a waiver of any other
term, nor shall a waiver of, or failure to enforce, a term in one instance be
deemed a continuing waiver or a waiver of the provision itself.

     

    17.  
Nature of
Relationship. Nothing herein shall
be construed to place the parties in a relationship of employees, agents,
partners or joint venturers, and neither party shall have the power to obligate
or bind the other in any manner whatsoever.

     

    18.  
Notices. All communications, notices and exchanges of
information contemplated herein or required or permitted to be given hereunder
shall be in writing and shall be given when one of the parties deposits the same
via hand delivery, courier or Certified United States mail, postage prepaid,
addressed to the other party at its address set forth below:

     

    If to
CTCA:

     

    Cancer
Treatment Centers of America, Inc.

    1336
Basswood Road

    Schaumburg, Illinois 60173

    Attn:
Robert Mayo, Vice Chairman

     

    If to
AVAX:

     

    AVAX
Technologies, Inc

    2000
Hamilton Street, Suite 204

    Philadelphia, Pennsylvania 19130

    Attn:
Richard Rainey, CEO

     

    19.  
Entirety. This Agreement constitutes the parties’ entire
agreement and understanding with respect to the subject matter hereof, and
supersedes all prior oral and written agreements and
understandings.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    The
parties hereto have caused this Agreement to be executed by their respective
officers with full legal and corporate authority to do so as of the date first
above written.

     

    
      
        
          
            
              
                
                  
                    	
                            CANCER
      TREATMENT CENTERS

                          	 
      	
                            AVAX
      TECHNOLOGIES, INC.

                          
	
                            OF
      AMERICA, INC.

                          	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      
	
                            By: 

                          	
                            /s/
      Robert
      Mayo

                          	 
      	
                            By: 

                          	/s/
      Richard Rainey
	
                            Its

                          	
                            Vice
      Chairman

                          	 
      	
                            Its:

                          	CEO

                  

                

              

            

          

        

      

    

     

    
      
        
        

      

      
        8Unassociated Document

    Exhibit
10.29

    

      SERVICES,
LOAN AND SECURITY AGREEMENT

       

      This
Services, Loan and Security Agreement (“Agreement”) is made and entered into as
of this 27th day of April, 2009 by and between AVAX Technologies, Inc., a New
York corporation with headquarters located at 2000 Hamilton Street Suite 204,
Philadelphia, Pennsylvania 19130 (“AVAX”), and Cancer Treatment Centers of
America, Inc., an Illinois corporation with headquarters located at 1336
Basswood Road, Schaumburg, Illinois 60173 (“CTCA”).

       

      RECITALS

       

      A. In 2007 CTCA
and AVAX entered into that certain Production Agreement, a copy of which is
attached hereto as Exhibit A (the “Production Agreement”).  Pursuant to the
Production Agreement, AVAX was required to operate CTCA performed all of its
operate its GMP laboratory in Philadelphia, Pennsylvania (the “GMP Lab”) and
fulfill production obligations for biological vaccines and CTCA was obligated to
make certain payments to AVAX and to purchase and install in the GMP Lab a
Beckman-Coulter Flow Cytometer and a Miltenyi Cell Separator unit (collectively,
the “CTCA Equipment”).

       

      B. CTCA has
performed all of its obligations under the Production Agreement, including
advancing funds to AVAX in the amount of $250,000 at execution of the Production
Agreement and making a further advance of $150,000 in December, 2008 (such
$400,000 is hereinafter referred to in the aggregate as the
“Advance”).

       

      C. AVAX has been
unable to perform many of its obligations and is in breach of the terms of the
Production Agreement.  AVAX is currently unable to continue to operate it’s
the GMP Lab, and is indebted to several creditors, including CTCA and AVAX’s
landlord Rodin Market Partners LP (“Rodin”).

       

      D. AVAX has
requested financial and operational assistance from CTCA in order to prevent the
closing of the GMP Lab. CTCA is willing to provide to AVAX financial and
operational assistance on the terms and conditions contained in this
Agreement.

       

      AGREEMENTS

       

      For and
in consideration of the mutual covenants contained herein, and other valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto agree as follows:

       

      1. 
Services of CTCA.  During
the term of this Agreement, CTCA will control the operation and maintenance of
the GMP Lab for a period of six (6) months, or less if determined by CTCA in its
sole discretion and communicated to AVAX in writing.  During such period in
which CTCA operates and maintains the GMP Lab, CTCA will advance to AVAX the
costs of operations, including the rent payable to Rodin for such months of
operation; CTCA will pay to Rodin on behalf of AVAX all prior rent set forth on
the attached Schedule A, as well as the rent for the months of April and
May.  AVAX  hereby grants to CTCA the unrestricted right to
negotiate with all vendors and customers of the GMP Lab.

      
        
           

        

        
          1

          
            

          

        

        
           

        

      

      2. 
Release of Liability.  AVAX
hereby agrees that CTCA shall not be liable for any acts or omissions that it
undertakes while providing such services, other than if CTCA engages in willful
misconduct or gross negligence which results in liability; CTCA shall not be
liable to AVAX for any lost profits, consequential or incidental damages or
under any other theory arising out of the services performed.

       

      3. 
 Intellectual Property
Provisions.  AVAX hereby agrees that it will not transfer to any
person or entity the intellectual property rights in the know-how, technology,
patent rights or invention rights relating to the processes which are the
subject of the Production Agreement without securing for CTCA a license to
continue to use all such intellectual property in connection with the operation
of the GMP Lab.  AVAX further agrees that any discovery, invention or other
intellectual property relating to the GMP Lab and any processing performed
therein that may be developed by during the conduct of this Agreement shall be
the sole property of CTCA.  While operating the GMP Lab CTCA will have the
right to enter into relationships with other parties, including Coronado
Biosciences, which relationships will remain CTCA’s and will not inure to the
benefit of AVAX unless assigned by CTCA in CTCA’s sole discretion.

       

      
        4.
Financial Terms; Loan and Security
Interest.  All of CTCA’s costs advanced (including
existing rental obligations,  rent for succeeding calendar months, and
the expense of Henry Schea and the other staff on premises) will be deemed to be
a “loan” to AVAX (the “Loan”).   The Loan shall bear interest at the
rate of 6%.  AVAX will execute and deliver one or more promissory notes in
form acceptable to CTCA to evidence the Loan under this
Agreement.

      

       

      (a)  On
August 31, 2009, or earlier if AVAX acquires financing, AVAX will repay CTCA all
of the Loan and interest, as well as the Advance.  AVAX may prepay the Loan
and the Advance in part or in full at anytime without penalty.

       

      (b)  To
secure repayment by AVAX of the Loan, AVAX hereby grants to CTCA a first
priority security interest in all of the personal property of AVAX located at or
relating to the GMP Lab, whether now owned or hereafter acquired or arising,
including all goods (including inventory, furniture, fixtures, equipment, and
any accessions thereto), general intangibles, insurance claims relating to the
foregoing and proceeds and products of the foregoing and all intellectual
property owned by AVAX and used in connection with the GMP Lab.

       

      (c) AVAX
specifically authorizes CTCA to prepare and file appropriate UCC Financing
Statements describing the security interest granted hereunder.

       

      (d)  CTCA
will not assume any of AVAX’s liabilities, and all obligations to third parties
will remain the legal obligations of AVAX.

      
        
           

        

        
          2

          
            

          

        

        
           

        

      

      5. 
 Conditions precedent to CTCA’s
providing the services and Loan.  CTCA’s obligations to provide the
services and the Loan hereunder are expressly conditioned on AVAX strictly
complying with each of the following obligations:

       

      (a)  CTCA
and AVAX receive from Rodin an acknowledgment that all rent has been paid
through the date hereof, that AVAX is not in default under the terms of the
Lease and that Rodin will not take any action to negatively impact AVAX’s quiet
enjoyment of the leased premises so long as AVAX continues to pay rent under the
Lease;

       

      (b)  AVAX
shall release Henry Schea from any and all employment restrictions upon request
by CTCA and AVAX agrees that CTCA (or its affiliates) may employ Henry Schea or
retain him as a consultant at any time;

       

      (c)  AVAX
acknowledges each of the following:  (i) that it is in breach of its
obligations under the Production Agreement; (ii) that it owes to CTCA the full
amount of the Advance; and (iii) that the Production Agreement remains
enforceable against AVAX in accordance with its terms, including all obligations
of repayment of the Advance; and

       

      (d)  AVAX
will continue to produce ovarian cancer vaccines in France for CTCA patients at
the request of CTCA (or its affiliate).

       

      6. 
Severability.  The
provisions of this Agreement shall be severable, and if any provision of this
Agreement shall be held or declared to be illegal, invalid or unenforceable,
such provision shall, if possible, be limited or construed so as to make it
valid and enforceable or, if such limitation or construction is not possible or
would be contrary to the parties’ manifest intentions, such provision shall be
stricken from this Agreement.  In any event, the remainder of this
Agreement shall continue in full force and effect.

       

      7. 
No Assignment.  This
Agreement may not be assigned by either party except that CTCA shall have the
right to assign its rights and obligations hereunder to an affiliate of CTCA so
long as such party assumes the assigned obligations in writing.

       

      8. 
Governing Law.  This
Agreement is deemed to be made and entered into pursuant to the laws of the
State of Illinois.  In the event of any dispute hereunder, this Agreement
shall be governed by and shall be construed and interpreted in accordance with
the laws of the State of Illinois.

       

      9. 
Waiver.  The terms of this
Agreement may be waived, and this Agreement may be amended, only in writing
signed by the party to be bound thereby.  A waiver of one term shall not be
construed as a waiver of any other term, nor shall a waiver of, or failure to
enforce, a term in one instance be deemed a continuing waiver or a waiver of the
provision itself.

      
        
           

        

        
          3

          
            

          

        

        
           

        

      

      10. 
Nature of Relationship. 
Nothing herein shall be construed to place the parties in a relationship of
employees, agents, partners or joint venturers, and neither party shall have the
power to obligate or bind the other in any manner whatsoever.

       

      11. 
Notices.  All
communications, notices and exchanges of information contemplated herein or
required or permitted to be given hereunder shall be in writing and shall be
given when one of the parties deposits the same via hand delivery, courier or
Certified United States mail, postage prepaid, addressed to the other party at
its address set forth below:

       

      If to
CTCA:

       

      Cancer
Treatment Centers of America, Inc.

      1336
Basswood Road

      Schaumburg,
Illinois 60173

      Attn:
Robert Mayo, Vice Chairman

       

      If to
AVAX:

       

      AVAX
Technologies, Inc

      2000
Hamilton Street, Suite 204 

      Philadelphia,
Pennsylvania 19130

      Attn:
John Prendergast, Chairman

       

      12. 
Entirety.  This Agreement
constitutes the parties’ entire agreement and understanding with respect to the
subject matter hereof, and supersedes all prior oral and written agreements and
understandings.

       

      The
parties hereto have caused this Agreement to be executed by their respective
officers with full legal and corporate authority to do so as of the date first
above written.

      

      
        
          
            	
                    CANCER
      TREATMENT CENTERS OF AMERICA, INC.

                  
	 
      
	
                    By:

                  	
                    /s/ Donald Braun

                  
	
                    Its  

                  	
                    Authorized
      Officer

                  
	 
      
	
                    AVAX
      TECHNOLOGIES, INC.

                  
	 
      
	
                    By:  

                  	
                    /s/
      John
      Prendergast

                  
	
                    Its:

                  	
                    Chairman

                  

          

        

      

      
        
           

        

        
          4

          
            

          

        

        
           

        

      

      Exhibit
B

      
      

      Form of
Note

       

      PROMISSORY
NOTE

       

      
        
          	
                  April
      27, 2009

                	
                  Schaumburg,
      Illinois    

                

        

      

      

      The
undersigned, for value received, promises to pay to the order of Cancer
Treatment Centers of America, Inc. (the “Lender”) at the principal office of
Lender in Schaumburg, Illinois the aggregate unpaid amount of all Loans made to
the undersigned by the Lender pursuant to the Services, Loan and Security
Agreement referred to below (as shown on the schedule attached hereto (and any
continuation thereof) or in the records of the Lender), such principal amount to
be payable on or before August 31, 2009.

       

      The
undersigned further promises to pay interest on the unpaid principal amount of
all amounts of the Loan from the date of such advance until the Loan is paid in
full, payable at the annual rate of six percent (6%).  Payments of both
principal and interest are to be made in lawful money of the United States of
America.

       

      This Note
evidences indebtedness incurred under, and is subject to the terms and
provisions of, the Services, Loan and Security Agreement, dated as of April 1,
2009 among Lender and the undersigned.

       

      This Note
is made under and governed by the laws of the State of Illinois applicable to
contracts made and to be performed entirely within such State.

      

      
        
          	
                  AVAX Technologies, Inc., a New York

                
	
                  corporation

                
	 
      
	
                  By:

                	
                        
                    /s/
      John Prendergast

                  

                
	
                  Name:  

                	
                  John Prendergast

                
	
                  Title:

                	
                  Chairman

                

        

      

      
        
           

        

        
          5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00183-of-00352.parquet"}]]